UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/577,861	11/01/2006	Nils Carlin	CARL3006/REF	9697
23364 BACON & THO	7590 01/30/200 OMAS, PLLC	EXAMINER		
625 SLATERS LANE			PORTNER, VIRGINIA ALLEN	
FOURTH FLOOR ALEXANDRIA, VA 22314-1176			ART UNIT	PAPER NUMBER
	•		1645	
			MAIL DATE	DELIVERY MODE
			01/30/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/577,861	CARLIN ET AL.
Office Action Summary	Examiner	Art Unit
	GINNY PORTNER	1645
The MAILING DATE of this communication ap Period for Reply	ppears on the cover sheet with the	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPOWHICHEVER IS LONGER, FROM THE MAILING IF Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication.  If NO period for reply is specified above, the maximum statutory perior. Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATIO 1.136(a). In no event, however, may a reply be tid d will apply and will expire SIX (6) MONTHS from the, cause the application to become ABANDONE	N. mely filed  the mailing date of this communication. ED (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on 28.      This action is <b>FINAL</b> . 2b) ☐ This action is <b>FINAL</b> .      Since this application is in condition for allow closed in accordance with the practice under	is action is non-final. ance except for formal matters, pr	
Disposition of Claims		
4) ⊠ Claim(s) 1-14 is/are pending in the applicatio 4a) Of the above claim(s) is/are withdres 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) 1-14 are subject to restriction and/or	awn from consideration.	
Application Papers		
9) The specification is objected to by the Examir 10) The drawing(s) filed on is/are: a) according an applicant may not request that any objection to the Replacement drawing sheet(s) including the corresponding to the specific part of	ecepted or b) objected to by the e drawing(s) be held in abeyance. Se ection is required if the drawing(s) is ob	e 37 CFR 1.85(a). ojected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bure.  * See the attached detailed Office action for a list	nts have been received. nts have been received in Applicat fority documents have been receiv au (PCT Rule 17.2(a)).	ion No ed in this National Stage
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date	4)  Interview Summary Paper No(s)/Mail D 5)  Notice of Informal I 6)  Other:	ate

Application/Control Number: 10/577,861 Page 2

Art Unit: 1645

## **DETAILED ACTION**

Claims 1-14 are pending.

## Election/Restrictions

1. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

- a. An expression system for CTB
- b. An expression system for CTB & a heterologous protein, specifically LTB

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

- 2. The claims are deemed to correspond to the species listed above in the following manner:
  - Claims 1-5, 8-14 are directed to species a) CTB;
  - Claims 6-7 are directed to species b) CTB & heterologous protein (claim 6), specifically LTB(claim 7)

Application/Control Number: 10/577,861

Art Unit: 1645

The following claim(s) are generic: no claims are generic.

3. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

Page 3

- 4. The first appearing invention is directed to an expression system for cholera toxin Beta subunit, the system comprising a Vibrio cholera host cell lacking a thyA gene (chromosomal inactivation), together with an expression vector that comprises a thyA gene and the coding sequence of the CTB gene lacking the flanking sequences outside the gene, the expression vector being less than 5 kb in size
- 5. The first appearing invention's claimed special technical feature is described by Liang et al, October 1, 2003 (reference cited on Applicant's US PTO 1449).
- Liang et al disclose Vibrio cholera strain IEM101-T, which is a thymidine-auxotrophic strain (see page 5499, col. 2, paragraph 2, fist sentence).
- The thyA auxotrophic strain of Vibrio cholera was transformed to comprise an expression vector (see page 5500, col. 2, "Results" section, bottom of first paragraph) referred to as pUTBL 1-5 (see Fig. 1, page 5500, top left corner).
  - a. The pUTBL1-5 plasmid comprises ctxB which is described to be a 1.15 kb XbaI fragment of the ctxB gene.
  - b. The thyA sequence is an E.coli thyA coding sequence which is known to be about 1.4 to 1.5 kb (see paragraph [0176, US PG-pub 20080014619]) and
  - c. the bla / ori are known to be about 1.4 kb (see Table 1, US PG-Pub 20030143745).

The size of the plasmid expression vector pUTBL1-5 is therefore about 3.95 to 4.05 kb in size, which is less that 5 kb in size. Liang et al describe the first

Application/Control Number: 10/577,861

Art Unit: 1645

appearing special technical feature, which therefore does not make a contribution over the prior art. In light of Liang et al describing the first appearing special technical feature, a lack of unity of invention exists, and the two claimed species are not so linked by a special technical feature that makes a contribution over the prior art.

Page 4

6. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GINNY PORTNER whose telephone number is (571)272-0862. The examiner can normally be reached on flextime, but usually M-F, alternate Fridays off.

Application/Control Number: 10/577,861 Page 5

Art Unit: 1645

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert Mondesi can be reached on 571-272-0956. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Ginny Portner/ Examiner, Art Unit 1645 January 27, 2008

/Robert B Mondesi/ Supervisory Patent Examiner, Art Unit 1645